Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Real-time Estimate Cboe BZX  -  10:29 2022-11-28 am EST
52.24 USD   +0.02%
11/10Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
11/04RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperform Rating
MT
11/03Intra-Cellular Therapies Reports Narrower Q3 Loss, Higher Revenue; Shares Jump
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1 8962 5494 2644 946--
Enterprise Value (EV)1 1 6721 8923 8504 6754 7104 719
P/E ratio -12,8x-9,85x-15,0x-18,2x-32,3x289x
Yield ------
Capitalization / Revenue 31 282x112x50,9x19,9x11,3x7,35x
EV / Revenue 27 586x82,9x45,9x18,8x10,7x7,01x
EV / EBITDA -10,9x-8,20x-13,5x-16,8x-21,5x-87,3x
Price to Book 9,77x3,90x10,2x7,87x8,94x7,76x
Nbr of stocks (in thousands) 55 26180 15881 46394 705--
Reference price (USD) 34,331,852,352,252,252,2
Announcement Date 03/02/202002/25/202103/01/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 0,0622,883,8248439673
EBITDA1 -154-231-285-278-220-54,0
Operating profit (EBIT)1 -154-231-286-274-16513,3
Operating Margin -254 103%-1 014%-341%-110%-37,7%1,98%
Pre-Tax Profit (EBT)1 -148-227-284-272-12650,2
Net income1 -148-227-284-271-14532,7
Net margin -243 726%-995%-339%-109%-33,1%4,87%
EPS2 -2,68-3,23-3,50-2,88-1,620,18
Dividend per Share2 ------
Announcement Date 03/02/202002/25/202103/01/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 35,055,671,986,688,599,0
EBITDA1 -72,5-87,8-55,5-66,0--
Operating profit (EBIT)1 -72,7-87,9-55,6-55,9-62,9-57,8
Operating Margin -208%-158%-77,4%-64,5%-71,1%-58,4%
Pre-Tax Profit (EBT)1 -72,1-86,6-53,5-59,0-53,5-50,6
Net income1 -72,1-86,6-53,5-55,8-53,5-50,6
Net margin -206%-156%-74,5%-64,4%-60,4%-51,1%
EPS2 -0,78-0,92-0,57-0,61-0,62-0,58
Dividend per Share ------
Announcement Date 05/10/202208/09/202211/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 224657414271237228
Leverage (Debt / EBITDA) 1,46x2,85x1,45x0,98x1,08x4,21x
Free Cash Flow1 -128-203-260-292-1728,20
ROE (Net Profit / Equities) -57,6%-53,3%-52,9%-55,4%-39,7%-9,21%
Shareholders' equity1 256426537490367-356
ROA (Net Profit / Asset) -48,6%-46,9%-47,1%-47,4%-40,2%-25,1%
Assets1 304484604573361-131
Book Value Per Share2 3,518,165,146,645,846,73
Cash Flow per Share2 -2,32-3,27-3,19-2,86-1,59-
Capex1 0,700,270,331,081,722,57
Capex / Sales 1 156%1,17%0,39%0,44%0,39%0,38%
Announcement Date 03/02/202002/25/202103/01/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 4 946 444 970
Net sales (USD) 83 803 020
Number of employees 512
Sales / Employee (USD) 163 678
Free-Float 97,4%
Free-Float capitalization (USD) 4 817 185 330
Avg. Exchange 20 sessions (USD) 42 770 304
Average Daily Capital Traded 0,86%
EPS & Dividend